soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Semaglutide cardiovascular outcomes align more

Most clients begin noticing brighter, more even-toned skin after several sessions, with continued improvement over a full treatment course

Figure 3 Early immune cell infiltration in rodent stroke is dominated by neutrophils and macrophages/microglia, whereas in human ischemic stroke it is different, consisting mainly of neutrophils and T cells (92)

Retatrutide is not currently licensed by the MHRA for weight loss in the UK, so it cannot legally be prescribed or supplied as an approved weight loss treatment

Combine Semaglutide With a Healthy Diet Focus on Protein First One of the most important things you can do while on semaglutide is eat enough protein

Kunutsor SK, Seidu S (2025)